GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors

Inclusion Criteria: * The patient or his legal representative is able to understand and voluntarily sign a written informed consent (before commencing this study and any research procedure); * Age ≥18 years old, male or female; * KRAS G12C mutant advanced solid tumor; * ECOG Performance Status of 0 or 1 * At least one measurable lesion as defined by RECIST 1.1 Exclusion Criteria: * acute myocardial infarction, unstable angina pectoris, coronary artery bypass grafting, cerebrovascular accident, or transient ischemic attack within 6 months before first administration; Grade III-IV heart failure based on the New York Heart Association Cardiac Function Scale at screening; During screening, echocardiography (ECHO) showed left ventricular ejection fraction (LVEF) ≤50%; * Patients who have a history of severe allergy, or have a history of allergy to the experimental drug/any excipient/combination drug, or have a history of allergy to multiple drugs; * There is an active infection (≥ grade 2) requiring anti-infective treatment or an unexplained fever exceeding 38 ° C within 28 days before the first dose; * Any toxicity from previous antitumor therapy prior to initial administration has not returned to CTCAE 5.0 rating ≤ Class 1 (unless hair loss, grade 2 peripheral neuropathy, and/or other grade ≤2 adverse events that do not pose a safety risk); * Pregnant and lactating women; * The investigator considers that there are any clinical or laboratory abnormalities or other reasons to be unsuitable for participating in this clinical study.